About Uteron Pharma
Uteron Pharma is a company based in Liege (Belgium) founded in 2002 by Jean Michel Foidart and Stijn Van Rompay was acquired by Teva Pharmaceuticals in January 2013. It operates as a B2B. Uteron Pharma has raised $31.09 million across 3 funding rounds from investors including Teva Pharmaceuticals, Nomainvest and Saffelberg Investments. Uteron Pharma operates in a competitive market with competitors including Daré Bioscience, Aspivix, Femasys, Adiana and RemovAid, among others.
- Headquarter Liege, Belgium
- Founders Jean Michel Foidart, Stijn Van Rompay
- SectorsHealthcare
- Website uteron.com
- Acquired by Teva Pharmaceuticals (Jan 2013)
- Total Equity Funding$31.09M (USD)
in 3 rounds
- Latest Funding Round$18.68M (USD), Series B
Mar 2012
- InvestorsTeva Pharmaceuticals
& 5 more
- Acquired byTeva Pharmaceuticals
(Jan 2013)
Funding Insights of Uteron Pharma
Uteron Pharma has successfully raised a total of $31.09M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18.68 million completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.09M
- Total Rounds 3
- Last Round Series B — $18.68M
- First Round $10.37M
(May 2011)
- Investors Count 5
All 3 funding rounds of Uteron Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2012 | $18.68M | Series B | – | – | |
| Sep 2011 | $2.04M | Series A | – | – | |
| May 2011 | $10.37M | Series A | – | – | – |
6 investors in total: 6 institutional.
Investors in Uteron Pharma
Uteron Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Teva Pharmaceuticals, Nomainvest and Saffelberg Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | saffelberg.com | - | |
Buyouts are pursued by SRIW as a private equity firm. | – | sriw.be | Liege, Belgium | |
Noshaq is recognized as a Liège-based investment fund providing financing solutions. | – | noshaq.be | Liege, Belgium | |
Noel family investments are managed by this family office. | 1950 | nomainvest.eu | Eupen, Belgium | |
Trust Capital is engaged in online trading and brokerage services. | – | trustcapital.com | lle Du Port, Seychelles | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel |
Investor details for Uteron Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Uteron Pharma
2 people are tracked at Uteron Pharma (2 in leadership).
| Name | Role | Group |
|---|---|---|
Jean Michel Foidart | Co-Founder | Leadership |
Stijn Van Rompay | Founder | Leadership |
Complete people profiles for Uteron Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Uteron Pharma
4 dated milestones of Uteron Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Uteron Pharma is founded.
- Funding First funding round of $10.4M.
- Funding Latest funding round, Series B, of $18.7M.
- Exit Acquired by Teva Pharmaceuticals.
Competitors of Uteron Pharma
Uteron Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Aspivix, Femasys, Adiana and RemovAid, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| darebioscience.com | 2005 | San Diego, United States | – | 30 | Non-hormonal pharmaceutical products for female contraceptives are developed. | |
| aspivix.com | 2015 | Lausanne, Switzerland | $7.01M | – | A next-generation suction-based cervical device for gynecology is provided. | |
| femasys.com | 2004 | Atlanta, United States | $69.22M | 25 | Medical devices for women's healthcare are developed and provided. | |
| adiana.com | 1997 | Marlborough, United States | $23M | – | Transcervical sterilization systems for permanent birth control are developed. | |
| removaid.com | 2012 | Oslo, Norway | – | 5 | Medical devices for subdermal implant removal are developed. | |
| herahealthsolutions.com | 2017 | Dallas, United States | $227,358 | – | Contraceptive arm implants are developed for female birth control. |
Detailed competitors of Uteron Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uteron Pharma
Complete news archive for Uteron Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Uteron Pharma
10 companies that operate in the same segment as Uteron Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Uteron Pharma
Uteron Pharma was founded in 2002 and raised its 1st funding round 9 years after it was founded.
Uteron Pharma is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Uteron Pharma is a funded company, having raised a total of $31.09M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10.37M, raised on May 2011.
Uteron Pharma develops products dedicated to female healthcare solutions through providing healthcare solutions, producing pharmaceutical products, womens health, and developing products. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Uteron Pharma's top competitors include Daré Bioscience, Femasys and Aspivix.
Uteron Pharma has 6 investors. Key investors include Teva Pharmaceuticals, Nomainvest, Saffelberg Investments, SRIW, and Noshaq.
Yes. Uteron Pharma was acquired by Teva Pharmaceuticals in January 2013.